Abstract
Background
Egypt has witnessed elevated incidence rates of multidrug-resistant Klebsiella pneumoniae infections in intensive care units (ICUs). The treatment of these infections is becoming more challenging whilst colistin-carbapenem-resistant K. pneumoniae is upsurging. Due to the insufficiently available data on the genomic features of colistin-resistant K. pneumoniae in Egypt, it was important to fill in the gap and explore the genomic characteristics, as well as the antimicrobial resistance, the virulence determinants, and the molecular mechanisms of colistin resistance in such a lethal pathogen.
Methods
Seventeen colistin-resistant clinical K. pneumoniae isolates were collected from ICUs in Alexandria, Egypt in a 6-month period in 2020. Colistin resistance was phenotypically detected by modified rapid polymyxin Nordmann/Poirel and broth microdilution techniques. The isolates susceptibility to 20 antimicrobials was determined using Kirby-Bauer disk diffusion method. Whole genome sequencing and bioinformatic analysis were employed for exploring the virulome, resistome, and the genetic basis of colistin resistance mechanisms.
Results
Out of the tested K. pneumoniae isolates, 82.35% were extensively drug-resistant and 17.65% were multidrug-resistant. Promising susceptibility levels towards tigecycline (88.24%) and doxycycline (52.94%) were detected. Population structure analysis revealed seven sequence types (ST) and K-types: ST383-K30, ST147-K64, ST17-K25, ST111-K63, ST11-K15, ST14-K2, and ST525-K45. Virulome analysis revealed yersiniabactin, aerobactin, and salmochelin siderophore systems in ˃ 50% of the population. Hypervirulence biomarkers, iucA (52.94%) and rmpA/A2 (5.88%) were detected. Extended-spectrum β-lactamase- and carbapenemase-producers accounted for 94.12% of the population, with blaCTX-M-15, blaNDM-5, and blaOXA-48 reaching 64.71%, 82.35%, and 82.35%, respectively. Chromosomal alterations in mgrB (82.35%) were the most prevailing colistin resistance-associated genetic change followed by deleterious mutations in ArnT (23.53%, L54H and G164S), PmrA (11.76%, G53V and D86E), PmrB (11.76%, T89P and T134P), PmrC (11.76%, S257L), PhoQ (5.88%, L322Q and Q435H), and ArnB (5.88%, G47D) along with the acquisition of mcr-1.1 by a single isolate of ST525.
Conclusions
In this study, we present the genotypic colistin resistance mechanisms in K. pneumoniae isolated in Egypt. More effective antibiotic stewardship protocols must be implemented by Egyptian health authorities to restrain this hazard and safeguard the future utility of colistin. This is the first characterization of a complete sequence of mcr-1.1-bearing IncHI2/IncHI2A plasmid recovered from K. pneumoniae clinical isolate belonging to the emerging high-risk clone ST525.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12941-023-00632-9.
Keywords: Klebsiella pneumoniae, WGS, Colistin resistance, ICU, Egypt, mgrB, mcr-1.1, XDR, MPNP
Background
Klebsiella pneumoniae, the most worrisome of the genus Klebsiella, accounts for about one-third of Gram-negative infections including hospital-acquired septicemia, pneumonia, meningitis, as well as surgical site, wound, and urinary tract infections [1]. These infections are life-threatening, affecting neonates and the elderly in intensive care units (ICUs) [1]. The problem is emphasized in the ICUs of lower middle-income countries where multidrug-resistant (MDR) K. pneumoniae is responsible for 15% of ICU-acquired infections [2]. As a part of this area, Egypt has witnessed elevated incidence rates of MDR K. pneumoniae recovered from patients admitted to ICUs reaching about 30% in 2021 [3]. The treatment of MDR K. pneumoniae infections is challenging and one of the treatment pillars for its eradication is carbapenem therapy [4]. As a consequence of the extensive usage of carbapenems, carbapenem-resistant K. pneumoniae (CRKP) began to upsurge more frequently in the past years, raising an alarm that effective treatment options are diminishing [3, 5]. CRKP emergence is linked to the global spread of carbapenemases, particularly, K. pneumoniae carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), and oxacillinase-48 (OXA-48) [6]. As a result, World Health Organization (WHO) published a list of antibiotic-resistant priority pathogens where carbapenem-resistant Enterobacteriaceae came at the first tier of the list, being identified as microorganisms of “critical priority” [7].
To fight against carbapenem resistance, colistin made a comeback to the forefront lines, becoming an antibiotic of last resort [8]. Colistin is a cationic polypeptide targeting mainly the negatively charged lipid A of the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria. Upon this electrostatic interaction, the bacterial membrane destabilizes, and the intracellular contents leak out causing bacterial death [9]. Unfortunately, colistin has witnessed rapid global resistance following its revival [8]. According to a systematic review conducted between 1987 and 2020, the universal incidence rate of colistin-resistant K. pneumoniae (ColRKp) was reported to be approximately 12%, comprising escalating continental trends reaching 3%, 10%, 16%, and 19%, in Africa, Asia, Europe, and America, respectively [10]. At the national level, the frequency of ColRKp reached 9.4% as reported by Zafer et al. conducting their study at the National Cancer Institute of Cairo University in 2019 [11]. It has been established that decreased susceptibility to colistin in K. pneumoniae is mainly attributed to mutations and genetic modifications in the chromosomally encoded genes, particularly, mgrB, phoP/phoQ, pmrA/pmrB, and crrB, and/or through the horizontal transfer of plasmid-mediated mobile colistin resistance (mcr) genes [12]. Among the ten different variants of mcr genes (mcr-1 to mcr-10) reported so far, mcr-1 remains the most dominant one universally [12, 13]. The worldwide dispersion of this gene in K. pneumoniae isolates has been facilitated by its carriage on a wide array of highly transferable plasmids of various incompatibility types, such as IncX4, IncI2, IncHI2, IncHII, IncFIIB, and IncP [12].
Both mutational and transferable mechanisms of colistin resistance result in a chemical alteration of lipid A molecule of the bacterial LPS via the addition of positively charged moieties, such as 4-amino-4-deoxy-l-arabinose (L-Ara4N) or phosphoethanolamine (pEtN), thus decreasing the lipid A negative charge and lowering the binding affinity of colistin to its target site [14, 15]. Nowadays, colistin is enlisted among the reserve group of antibiotics in the WHO list of essential medicines and its use is highly recommended to be tailored to specific clinical settings when no other treatment options are available [16].
In Egypt, no data was published on the molecular mechanisms of colistin resistance in ColRKp clinical isolates until 2018 [17]. To date, only a few studies had reported the occurrence of mcr-1, mcr-2, and mutated mgrB genes among the Egyptian isolates [11, 18–21]. In the current study, whole genome sequencing (WGS) approach was used to explore the genomic features of ColRKp isolates. Uncovering the resistome and virulome, as well as shedding light on the genetic basis of the mechanisms underlying colistin resistance will certainly provide a better understanding of the emergence and dissemination of this type of resistance in Egypt. Hence, the Egyptian health authorities will have the potential to develop more effective antibiotic stewardship protocols to restrain this hazard and safeguard the future utility of colistin. This is the first study presenting the detailed genomic characterization of ColRKp clinical isolates in Egypt and issuing a complete sequence of mcr-1.1-bearing IncHI2/IncHI2A plasmid recovered from a clinical isolate of K. pneumoniae belonging to the emerging high-risk clone ST525.
Methods
Collection and identification of clinical bacterial isolates
Klebsiella spp. isolates were obtained from a private hospital laboratory that has 8 satellite branches in Alexandria, Egypt, with a lab-to-lab patient service that almost covers the whole governorate of Alexandria. This laboratory receives about 400 to 500 Klebsiella spp. isolates every month. The criteria for collecting the isolates from this laboratory were set to be: “Klebsiella spp.”, “colistin resistance”, and “ICU patients”. Accordingly, a total of 17 colistin-resistant (Col-R) Klebsiella spp., numbered from K1 to K17, was obtained within a period of 6 months from July to December 2020. All isolates were preserved at − 20 °C in Luria-Bertani broth (LB, HiMedia, Mumbai, India) containing 20% glycerol and archived at − 80 °C. Before use, a fresh culture of each of the collected isolates was obtained by cultivation on MacConkey’s agar (HiMedia, Mumbai, India) and incubation for 24 h at 37 °C. The identification of the isolates was performed by Gram and capsule staining, followed by in-house prepared biochemical tests including indole production, methyl red, Voges-Proskauer, citrate utilization, triple-sugar iron, urease, and catalase tests. Further identification at the species level was performed using Vitek 2 compact system (bioMérieux, Marcy-L’Etoile, France) according to the manufacturer’s instructions.
Modified rapid polymyxin Nordmann/Poirel test (MPNP)
In rapid polymyxin NP test (RPNP), the Col-R isolates metabolize the glucose present in the medium with the formation of acid that shifts the color of the phenol red pH indicator from orange to yellow, allowing the identification of these isolates through rapid visual observation [22]. The incorporation of EDTA in MPNP test increases the sensitivity of the technique enabling the detection of isolates harboring mcr-1 gene [23]. Briefly, freshly grown colonies on LB agar (HiMedia Lab., Mumbai, India) were used to prepare a suspension with an optical density equivalent to 3.0–3.5 McFarland (≈ 109 CFU/mL). A volume of 50 µL of this suspension was added to a well in a 96-well polystyrene plate containing 150 µL of one of the following solutions: RPNP solution (2.5% cation-adjusted Mueller–Hinton broth (CAMHB, HiMedia Laboratories, Mumbai, India); 0.005% phenol red (Sigma Chemical, St. Louis, USA); 1% D (+)-glucose anhydrous (Thermo Fisher Scientific, UK)), RPNP mixed with 5 µg/mL of colistin sulfate (Sigma Chemical, St. Louis, USA), RPNP supplemented with 80 µg/mL EDTA (Sigma Chemical, St. Louis, USA), and RPNP incorporating both colistin and EDTA [22, 23]. The plate was incubated at 37 °C unsealed and visually monitored during a period of 4 h for color change [22]. A solution of 0.85% NaCl was used as sterility control, while colistin-sensitive (Col-S) E. coli ATCC 8739 and Col-R E. coli EC13655 [24] were included as reference negative and positive controls, respectively.
Antimicrobial susceptibility testing
The susceptibility of K. pneumoniae isolates to 20 antimicrobials was determined by Kirby-Bauer disk diffusion method. The disks for the following antibiotics were purchased from HiMedia Laboratories (Mumbai, India): piperacillin (PI), piperacillin/tazobactam (PIT), amoxicillin/clavulanate (AMC), ceftazidime (CAZ), ceftriaxone (CTR), cefepime (CPM), aztreonam (AT), imipenem (IPM), meropenem (MRP), ertapenem (ETP), amikacin (AK), gentamicin (GEN), tobramycin (TOB), azithromycin (AZ), doxycycline (DO), tigecycline (TGC), ciprofloxacin (CIP), and levofloxacin (LE). Whereas the disks for ceftazidime/avibactam (CZA) and sulfamethoxazole/trimethoprim (SXT) were obtained from Oxoid (Hampshire, UK). The test was carried out according to the Clinical Laboratory Standards Institute (CLSI, 2021) guidelines using Mueller–Hinton agar (HiMedia Laboratories, Mumbai, India) [25] and the results were interpreted in accordance with the breakpoints indicated in CLSI, except when using TGC disks, where the Food and Drug Administration (FDA) breakpoints for Enterobacteriaceae were adopted [26]. The broth microdilution technique (BMD) was performed in triplicate to determine the minimum inhibitory concentration (MIC) of colistin against the collected isolates using cation-adjusted Mueller–Hinton broth (CAMHB, HiMedia Laboratories, Mumbai, India), following the protocols recommended in M100-ED31 of the 2021 CLSI which considered isolates with a colistin MIC value of ≥ 4 µg/mL to be resistant. The quality control strain E. coli ATCC 25922 was included in the test.
Whole genome sequencing (WGS)
WGS of the 17 tested isolates was carried out within the facility of the sequencing department at Quadram Research Institute, Norwich, UK. Bacterial DNA was extracted and purified using GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific, Vilnius, Lithuania) according to the manufacturer’s instructions. The extracted DNA was quantified using the Promega QuantiFluor® dsDNA System (Catalogue No. E2670), normalized to 5 ng/µL using PCR grade water, and run on a Promega GloMax® Discover Microplate Reader. Libraries were made using an Illumina 20-fold diluted DNA Prep reaction and amplified using custom 9 bp indexed primers. WGS was performed on an Illumina NextSeq 500 instrument using a High Output Flowcell NextSeq 500/550 High Output Kit v2.5 (300 Cycles, Illumina Catalogue 20024908) according to the Illumina denaturation and loading recommendations which included a 1% PhiX spike (PhiX Control v3 Illumina Catalogue FC-110-3001). The libraries were quantified using the GloMax and QuantiFluor® dsDNA kit. Libraries were pooled following quantification and the final pool was double-SPRI size selected between 0.5 and 0.7× bead volume using the beads supplied in the Illumina® DNA Prep kit. The final pool was quantified on a Qubit 3.0 instrument and run on a D5000 Screentape (Agilent Catalogue No. 5067-5579) using the Agilent tapestation4200 to calculate the final library pool molarity. The generated BCL files were converted to FASTQ format using bcl2fastq v2.20.0.422 software [27] for downstream analysis.
Bioinformatic analysis
The FASTQ files were quality-checked and processed using fastp v0.23 [28] where low quality nucleotides of Q-score < 20 were trimmed. Shovill v1.1.0 (https://github.com/tseemann/shovill) was used for de novo assembly and the quality was evaluated using QUAST v5.0.2 [29] for genome contiguity and BUSCO v5.2.2 [30] for genome completeness. The obtained contigs were queried utilizing the pipelines available on Center for Genomic Epidemiology (CGE) (https://www.genomicepidemiology.org/) (accessed on 31 May 2022) to perform multilocus sequencing typing (MLST v2.0) and to identify acquired antimicrobial resistance (AMR) genes (ResFinder v4.1). Chromosomal point mutations for cephalosporins, fluoroquinolones, and carbapenems resistance were identified (PointFinder v4.1) and plasmid incompatibility (Inc) groups were detected using PlasmidFinder v2.1. The Institut Pasteur website (https://bigsdb.pasteur.fr/klebsiella/) (accessed on 15 June 2022) was used for typing of wzi and wzc alleles and locating heavy metal resistance genes. Virulence genes were detected using the Institut Pasteur website and Virulence Factor Database (VFDB) [31]. Kaptive database was used for capsular (K) and lipopolysaccharide (O-antigen) locus typing (https://kaptive-web.erc.monash.edu/) (accessed on 20 June 2022). The presence of mcr variants was investigated using ResFinder v4.1. Chromosomal loci disruptions or alterations linked to colistin resistance (e.g., alterations in mgrB locus (gene and its promoter), the genetic environment of mgrB including kdgR, yobH, yebO, yobF, and cspC, phoPQ, pmrAB, pmrC, pmrD, crrB, arnBCADTEF operon, and ramA) were explored in silico using the nucleotide basic local alignment search (BLASTn) tool of National Center of Biotechnology Information (NCBI) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) by aligning the assembled contigs against the wild type gene sequence of K. pneumoniae subsp. pneumoniae HS11286 (GenBank accession number: NC_016845.1). Any change in the protein level was analyzed using the NCBI BLASTx tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastx&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) followed by the Protein Variation Effect Analyzer tool (PROVEAN) (https://provean.jcvi.org/index.php) (accessed on 6 June 2022) to predict the amino acids substitution/deletion effect on the functional biological activity of the protein. ISfinder was used to look for insertion sequences [32]. Finally, phylogenetic relatedness between isolates was investigated using CSI phylogeny [33] by setting NC_009648.1 as the reference genome. The phylogenetic tree was visualized using Interactive Tree of Life V6.5 (iTOL) [34].
Construction of mcr-1.1-bearing plasmid
PlasmidSPAdes v3.15.3 [35] was used to generate the plasmid contigs in sample K2. The node harboring mcr-1.1 was queried against K. pneumoniae (taxid:573) using BLASTn tool, followed by mapping all the generated plasmid contigs from the tested sample against the available plasmid sequences online. The complete sequence of the constructed plasmid pEGY_KP9814_MCR1 was generated by assembling multiple contigs while overlapping sequences were manually curated. The plasmid annotation was performed using the NCBI prokaryotic genome annotation pipeline (PGAP) [36]. Plasmid Inc groups and AMR genes were detected using PlasmidFinder v2.1 [37] and ResFinder v4.1 [38] tools, respectively. The circular comparison map between pEGY_KP9814_MCR1 and other similar plasmids was generated using CGview server v1.1.2 (http://stothard.afns.ualberta.ca/cgview_server/) (accessed on 1 April 2023) after mining similar plasmid sequences from NCBI. Comparative analysis of mcr-1.1 genetic environment was performed using Clinker [39].
Results
Clinical characteristics of the collected isolates
The collected isolates were preliminary identified as Klebsiella spp. by conventional methods (Additional file 1: Figs. S1 and S2) and their identities were further confirmed to be K. pneumoniae subspecies pneumoniae using Vitek 2 compact system. The clinical origin of these isolates was as follows: blood (n = 8), mini-bronchoalveolar lavage (mini-BAL, n = 3), tracheal aspirate (n = 2), urine (n = 2), swab (n = 1), and sputum (n = 1). Most of the isolates were recovered from geriatrics (n = 10) with a mean age of 67 years old, followed by neonates (n = 6) with an age range of 4–15 days, while a single isolate was obtained from a 32-year-old male. The detailed demographic data including clinical origin, age, gender, patient code, and date of collection are provided in Additional file 2: Table S1.
Phenotypic detection of colistin resistance
The MPNP test was performed for the initial screening of colistin resistance and the presumptive detection of mcr-1 gene. All isolates grew in the presence of colistin- and colistin/EDTA-containing RPNP solution, indicating colistin resistance and a presumptive absence of mcr-1, respectively. The growth of the tested isolates was evidenced by the color change of the pH indicator from orange to yellow (Additional file 1: Fig. S3). Colistin resistance was confirmed by BMD where isolates displayed colistin MIC values ranging from 8 to 128 µg/mL (Additional file 2: Table S2).
Genomic features of ColRKp isolates
WGS using Illumina short read sequencing technology was performed for the 17 ColRKp isolates. De novo assembly generated draft genomes with a size range of 5.4 to 6 Mb. The average number of contigs per isolate was 245 with an N50 of 114,109 bp and mean G+C content of 56.82%. Assembly statistics are provided in Additional file 2: Table S3. The population structure of K. pneumoniae strains was investigated using the genome sequence data and their phylogenetic relatedness is represented in Fig. 1 where each well-defined branch in the phylogenetic tree comprises strains of the same sequence types (ST) clustering together. Seven distinct STs featured the studied collection according to the MLST allelic analysis, out of which four STs were represented by more than one isolate: ST383 (7/17), ST147 (3/17), ST17 (2/17), and ST111(2/17), while ST11, ST14, and ST525 were displayed each by a single isolate. Kaptive database was used for capsular polysaccharide (K-type) and lipopolysaccharide (O-antigen) characterization. It predicted 7 different K-types: K-2, K-15, K-25, K-30, K-45, K-63, and K-64 which were found to be correlated with ST14, ST11, ST17, ST383, ST525, ST111, and ST147 lineages, respectively. The association of ST383 with K-30 capsular type appears to be the most ubiquitous in the collection. O-serotyping revealed 4 different O antigens: O1, O2A, O4, and O5, with O1 and O2A serotypes being the most abundant, accounting for 52.94% and 29.41% of the isolates, respectively. Each K-type, wzi, and wzc alleles were found to belong to the same ancestry lineages. Meanwhile, O-serotype was associated with variable STs (Fig. 1).
Virulence profiles of ColRKp isolates were investigated to infer to the isolates likelihood of causing severe infections. All isolates harbored the core pathogenicity factors, fim and mrk genes cluster, coding type 1 and type 3 fimbriae which are involved in the adherence and biofilm formation, respectively, as well as genes encoding the core siderophore enterobactin, entABCDEFS, responsible for iron scavenging from host cells. Additional acquired siderophore systems which contribute to K. pneumoniae virulence were detected in more than half of the population, namely: yersiniabactin (synthesized by ybtAEPQSTUX, regulated by irp1/2 and its receptor encoded by fyuA), aerobactin (encoded by iucABCD and transported into bacterial cells by its corresponding receptor encoded by iutA), and salmochelin (encoded by iro genes). None of the isolates harbored iroBCD genes, whereas both iroN and iroE were found in all of the isolates.
Noteworthy, yersinia high-pathogenicity island (HPI) which comprises ybtAEPQSTUX, irp1, irp2, and fyuA [40] was detected in 11 isolates: K5, K6, K8, K9, K10, K11, K12, K13, K14, K16, and K17. The presence of this HPI enables the producing isolates of enhanced iron sequestration and bacterial proliferation. The biomarker of hypervirulence, iucA, was detected in 9 isolates while rmpA/A2, regulator of mucoid phenotype, was found in a single isolate (Fig. 1). An additional pathway for iron transportation, kfu (Klebsiella ferric uptake) system, was found in K4 isolate. Additional virulence determinants including mucoviscosity-associated gene A (magA) and allantoin utilization genes (allS and allABCDR) were investigated using BLASTn tool and VFDB, respectively, however, they were not detected in any of the studied isolates.
Multiple heavy metal resistance genes coding for tellurium (ter), copper (pco), silver (sil), arsenic (ars), and mercury (mer) resistance were detected among the isolates with silR being present in all isolates and ars being exclusively found in K15 isolate. The distribution of virulence and heavy metal resistance genes among the isolates is detailed in Additional file 2: Table S4.
PlasmidFinder identified a total of 17 distinct plasmid replicon types with a minimum of 3 and a maximum of 7 in each of the isolates (Fig. 2). The most prevalent plasmid replicon type belonged to the Inc family, dominated by IncL and IncFIB(pQil) which were detected in 76.47% and 64.71% of the isolates, respectively. These were followed by IncFIIK, IncFIB(pNDM-Mar), and IncHI1B(pNDM-MAR) which prevailed in 58.82% of the investigated collection, with the latter two Incs co-existing together. Other Inc types were identified including IncFII, IncFIB(pKPHS1), IncFIBK, IncFIBK(pCAV1099-114), IncHI2/2A, and IncX3/M1/R. Three types of Col plasmid replicons were observed including ColRNAI (n = 4; 23.53%), Col440II (n = 3; 17.65%), and Col440I (n = 1; 5.88%). The plasmid replicon types for each isolate are listed in Additional file 2: Table S4.
Phenotypic antimicrobial resistance profile
The Kirby–Bauer disk diffusion method was employed to assess the susceptibility of ColRKp isolates to a panel of 20 antibiotics which were selected based on the CLSI guidelines provided for K. pneumoniae infections. More than half of the tested antibiotics (11/20) were ineffective against all the tested isolates, namely: PI, PIT, AMC, CTR, CAZ, CPM, MRP, ETP, TOB, CIP, and LE. A percentage of 94.12% of the isolates were resistant to CZA, IPM, and AZ. Moreover, high levels of resistance, exceeding 70%, were detected for AT, AK, GEN, and SXT. While most of the isolates showed alarming resistance levels to 18/20 of the evaluated antimicrobials, TGC and DO retained their efficacy against 88.24% and 52.94% of the studied isolates, respectively (Fig. 2). The tested K. pneumoniae isolates were predominately extensively drug-resistant (XDR) by being non-susceptible to at least one antibiotic in all but one or two investigated antimicrobial categories. Meanwhile, a small proportion (17.65%) of the isolates exhibited an MDR phenotype by displaying resistance to at least one agent in ≥ 3 antimicrobial classes (Fig. 2).
Genotypic analysis of antimicrobial resistance determinants
ResFinder identified multiple acquired AMR genes (Fig. 2) which are in line with the XDR and MDR phenotypes displayed by the isolates. All isolates were extended spectrum β-lactamase (ESBL) producers except for K13. The ESBL-encoding genes detected among the studied population were highly diverse comprising blaSHV-40, blaSHV-98, blaSHV-106, blaCTX-M-14b, blaCTX-M-15, blaCTX-M-163, blaCTX-M-194, and blaCTX-M-219, with blaCTX-M-15 and blaCTX-M-14b being the most frequently observed in 64.71% and 52.94% of the isolates, respectively. However, blaSHV-106,blaCTX-M-163, blaCTX-M-194, and blaCTX-M-219 were less common, being found in 5.88% of the isolates (Additional file 2: Table S4). Among carbapenemases, blaNDM genes were the most frequently encountered (n = 16), with blaNDM-5 variant being the most common among the isolates (n = 14) as well as blaOXA-48 with an equal prevalence, whereas blaKPC, blaVIM, and blaIMP were absent among the studied isolates. Additional β-lactamases including non-ESBLs were detected (Fig. 2) and their corresponding variants are listed in Additional file 2: Table S4. PointFinder analysis of ompK35, ompK36, and ompk37 genes encoding outer membrane proteins revealed multiple chromosomal mutations that have an impact in reducing membrane permeability (Additional file 2: Table S4). Thus, explaining the observed phenotypic resistance to carbapenems and cephalosporins for those isolates lacking carbapenemases or ESBL-encoding genes. Fifteen genes accountable for aminoglycosides resistance were recognized: aph(3′)-Ia, aph(3′)-VI, aph(3′)-VIb, aac(3)-IIa, aac(6′)-Il, aac(6′)-Ib, aac(6′)-Ib-Hangzhou, aac(6′)Ib-cr, armA, rmtF, aadA1, aadA2, aadA2b, strA, and strB (Additional file 2: Table S4). Among these genes, armA and rmtF which are associated with pan-aminoglycoside resistance were present in 7 isolates. The aminoglycoside resistance gene, aph(3′)-Ia, was the most abundant (n = 14) followed by aac(6′)Ib-cr (n = 13) which additionally confers resistance to ciprofloxacin (Additional file 2: Table S4). Moreover, fluoroquinolones resistance was mediated by three mechanisms: qnrS1 and qnrB1 plasmid-mediated genes, oqxAB chromosomally encoded efflux pump, and the chromosomal loci mutations detected in gyrA, parC, and acrR (Additional file 2: Table S4). Doxycycline resistance was mainly attributed to the acquisition of tetA gene while other variants of tet genes were completely absent.
Different variants of sul and dfrA genes (Additional file 2: Table S5) co-existed in 76.47% of the isolates mediating resistance to sulfamethoxazole and trimethoprim, respectively. A comparable distribution of sul1 and sul2 genes was observed among the isolates, with sul1 being detected in 76.47% and sul2 in 70.59% of the isolates. Additionally, the co-occurrence of both genes was spotted in 58.82% of the bacterial collection. Conversely, sul3 was less frequent, being detected in a single isolate, K2. Chloramphenicol resistance was primarily mediated by chloramphenicol acetyltransferases, catA1 and catB3, detected in 64.71% of isolates, whereas chloramphenicol efflux pumps, floR and cmlA, were carried by a single isolate, K2. Additional resistance determinants were detected for various classes of antimicrobials such as msr(E), mph(A), and mph(E) mediating resistance to macrolides; fosA encoding fosfomycin resistance and arr-2 and arr-3 coding for rifamycin resistance.
Molecular characterization of colistin resistance mechanisms
Screening for plasmid-mediated mcr genes by ResFinder revealed that a single isolate, K2 belonging to ST525, harbored mcr-1.1, while other mcr variants were completely absent among the investigated collection. Furthermore, the mcr-bearing isolate had additional chromosomal mutations in pmrA, pmrC, and arnT leading to D86E, S257L, and G164S deleterious substitutions, respectively, as predicted by PROVEAN tool. Inspection of further chromosomal mutations conferring colistin resistance showed deleterious substitutions within PhoQ (L322Q and Q435H in K6 isolate), PmrA (G53V in K9 isolate), PmrB (T134P in K7 isolate and T89P in K6 isolate), PmrC (S257L in K4 isolate), ArnB (G47D in K4), and ArnT (L54H in K1, K6 and K17 isolates). Relatively conserved PmrD, ArnA, and ArnF as well as wild-type PhoP, ArnC, ArnD, ArnE, RamA, KdgR, YobH, YebO, YobF, and CspC were detected in all isolates except K10 isolate which lacked the latter four proteins (Fig. 3). It was noted that isolates that were clustered to a specific ST possessed similar neutral amino acids substitution within PmrAB, PmrC, PmrD, ArnA, ArnF, and CrrB (Fig. 3). The crrB gene could not be detected in isolates belonging to the clonal groups ST383 and ST14. Alteration in mgrB locus appears to be the predominant mechanism mediating colistin resistance where it was encountered in 82.35% of the tested collection. Six isolates belonging to ST14, ST383, and ST17 had an ISKpn14 (member of IS1 family) insertional inactivation targeting different nucleotide positions in mgrB (Figs. 3 and 4b–e), while an insertional inactivation of the mgrB promoter by ISKpn14 was observed in K8 isolate (Figs. 3 and 4g). The disruption of mgrB at nucleotide position + 74 by a member of IS5 family, ISKpn26, was detected in two isolates of ST111 (Figs. 3 and 4f). Other alterations in mgrB included partial deletion of mgrB leading to the generation of truncated mgrB gene and an incomplete MgrB protein in three isolates (Figs. 3 and 4h, i), complete deletion of mgrB locus with the neighboring genes being completely (yebO, yobF, and cspC) and partially (yobH) deleted in K10 isolate, G109A mgrB chromosomal mutation leading to G37S deleterious amino acid substitution in K1 isolate, and a chromosomal mutation of guanine into adenine in the upstream region of mgrB, particularly at nucleotide position − 10, when referring to the first nucleotide upstream mgrB start codon as − 1 in K15 isolate. Collectively, our results indicate that genetic alterations associated with colistin resistance are diverse among the Egyptian strains, with K2 isolate being featured among the collection for having dual chromosomal and plasmid-mediated mechanisms of colistin resistance.
Of note, 88.24% of the isolates were colistin-resistant but TGC-sensitive, making this observation interesting for the investigation of additional genes related to colistin/TGC cross-resistance including the efflux pump mechanisms acrAB and soxSR. Wild-type gene and protein sequences were revealed across all isolates through comparative analysis against the reference sequence of K. pneumoniae HS11286.
Characterization of pEGY_KP9814_MCR1 plasmid and its comparison to similar plasmids
The mcr-1.1-bearing plasmid was harbored by a K. pneumoniae ST525 clinical isolate obtained from a tracheal aspirate of a male patient. The plasmid, designated pEGY_KP9814_MCR1 (GenBank ID OQ215737I), was 175,241 bp long with an IncHI2 and IncHI2A backbone. It contained 174 CDS and had an average G+C content of 46%. The plasmid harbored essential proteins responsible for plasmid replication (Rep), conjugative transfer (Tra and Trh), maintenance, and segregation (Par). Co-occurring AMR genes were identified alongside mcr-1.1 such as aadA1, aadA2b, tetA, cmlA1, and sul3, whereas sul3 was interrupted by IS1-like element IS1A family transposase. Furthermore, tellurium resistance genes (terBCDWYZ) and genes coding transposases were carried by the plasmid. Comparative analysis of pEGY_KP9814_MCR1 against similar published plasmids using BLASTn revealed high sequence identity with IncHI2 mcr-1-positive plasmids recovered from E. coli in Egypt namely pEGY1-MCR-1 of raw milk cheese origin (GenBank ID CP023143.1) and pEGYMCR_IncHI2 obtained from chicken carcass (GenBank ID MT499884.1), both exhibiting 99.99% sequence identity and query coverage of 96% and 95%, respectively. Moreover, pEGY_KP9814_MCR1 shared a significant sequence similarity to three IncHI2 plasmids of clinical origin identified in K. pneumoniae in Asia; pAN65-1 (GenBank ID MK355502.1) and pKP121-1-mcr (GenBank ID NZ_CP031850.1) in China, as well as pKP14052-MCR-1 (GenBank ID MH715960.1) in Taiwan, all showing 99.73% nucleotide identity and 93%, 93%, and 88% sequence length, respectively (Fig. 5a).
Genetic context of mcr-1.1
In silico analysis of the genetic environment of mcr-1.1 in pEGY_KP9814_MCR1 revealed a sole ISApl1 insertion sequence in the upstream region of mcr-1.1. A single upstream copy of ISApl1 was identified as well in pAN65-1 and pKP121-1-mcr, however, a composite transposon of ISApl1-mcr-1.1-orf-ISApl1 was carried by pEGYMCR_IncHI2, pEGY1-MCR-1, and pKP14052-MCR-1. Furthermore, the gene encoding phosphatase protein (PAP2) was located directly after mcr-1.1 in the previously published plasmids. Whereas pEGY_KP9814_MCR1 was distinguished by carrying a protein phosphatase (PP2C) at the downstream region of mcr-1.1 followed by a tellurium resistance gene (terY) (Fig. 5b). Marked similarity (100% nucleotide identity and 57% query coverage) was observed in the flanking regions surrounding mcr-1.1 in pEGY_KP9814_MCR1 and pEGY1-MCR-1, with the latter plasmid carrying similar hypothetical protein as in pEGY_KP9814_MCR1 and a partial sequence of PP2C. Comparing the genetic context of the remaining four plasmids with pEGY_KP9814_MCR1 revealed 99.89–100% nucleotide identity with varying query coverage (Fig. 5b).
Discussion
The global crisis of AMR had escalated during the last decade with the emergence of bacterial resistance to last resort antibiotics such as colistin, especially when it is encountered in a clinically problematic pathogen such as K. pneumoniae [1, 8]. In the presented work, we investigated the genomic features of ColRKp collected from adult and neonatal ICUs in Alexandria, Egypt, in a 6-month period. The clinical origin of 47% of the isolates was from blood cultures, similar to a study conducted at the National Cancer Institute of Cairo University [11] which signifies a worrying scenario due to the high risk of mortality caused by bloodstream infections, especially in case of colistin and carbapenem resistance [41].
The performed MPNP test detected colistin resistance in the 17 collected isolates and the results were confirmed by the recommended BMD technique, however, MPNP test failed to detect mcr-1.1 harbored by K2 isolate, which was identified subsequently by WGS. This could be justified by the presence of additional chromosomal mutations in this isolate impeding the EDTA-mediated inhibitory effect. Therefore, the growth of isolates in the presence of colistin/EDTA-containing RPNP solution might indicate the absence of mcr or the presence of mcr along with chromosomal mutations related to colistin resistance creating a false negative result similar to the one obtained in the current study. In addition, the sensitivity of this phenotypic test is indeed not comparable to the molecular detection methods of colistin resistance. Therefore, a cautious interpretation of the MPNP results is recommended along with cross-checking by molecular techniques for reliability.
The genomic analysis of the ColRKp isolates revealed a highly divergent genetic makeup comprising multiple STs, K- and O-types, thus, highlighting the genomic plasticity of the strains circulating in Egypt. ST383, an epidemic high-risk clone previously reported in ColRKp isolates in Greece [42], Lebanon [43], and Egypt [11], and known to carry carbapenemases [44], was encountered in 41.18% of the tested isolates harboring blaOXA-48 and/or blaNDM, which are among the carbapenemases frequently reported in Egypt [45]. Other ColRKp STs detected in our study: ST11, ST14, ST17, ST111, ST147, and ST525 have been witnessed disseminating globally [10, 46, 47]. Furthermore, O1 and O2 antigens accounted for 82.35% of the tested population, supporting the earlier finding that both serotypes are more frequently encountered in clinical K. pneumoniae isolates [48]. Therefore, genotyping of ColRKp isolates is essential to track the different clones and serotypes behind a threat endangering the global health situation.
Virulome analysis of the sequenced isolates highlighted the ubiquitous presence of capsular polysaccharide, LPS, fimABCDEFGHIK, and mrkABCDFHIJ gene clusters, which are essential pathogenicity factors for the early establishment of infection and bacterial evasion of host immune response [49]. The propensity of an infectious disease occurrence is further enhanced through the acquisition of yersiniabactin, aerobactin, and salmochelin siderophore systems [49] which were carried by ˃ 50% of the isolates, thus ensuring the thriving of K. pneumoniae isolates in iron deficient environment imposed by the host. Notably, iuc, which was carried by 52.94% of the isolates, is reported to play the utmost significant role in virulence among the four siderophore systems, both in vivo and in vitro [50]. Furthermore, iuc, rmpA, and rmpA2 were detected in K7 isolate of ST383 lineage. ST383 is a non-hypervirulent clone [51] and its acquisition of hypervirulence biomarkers is a concerning scenario that might elicit increased morbidity and mortality, similar to the fatal outbreak witnessed in China due to a classical ST11 harboring these biomarkers [52]. Another important observation is the isolates tolerance for heavy metals, a phenomenon postulated to arm the isolates with enhanced survival capabilities in environmental habitats beyond hospital settings [53]. In response to this, proactive strategies and periodically updated infection control measures are imperative to prevent potential hospital outbreaks and subsequent community epidemics with highly virulent strains.
By inspecting the antibiotic resistance profiles displayed by ColRKp isolates, alarmingly high rates (70–100%) of resistance were detected towards almost all tested antibiotics except for TGC and DO which showed better efficacy against 88.24% and 52.94% of the collected XDR/MDR isolates, respectively, pointing them out as the available option for combating K. pneumoniae infections. The resistance profile pictured in this work could be correlated to an international surveillance study conducted in the ICUs of 88 countries which drew attention to the increased rates of AMR in ICUs compared to other hospital departments [54]. This could be ascribed to the unconstrained use of antibiotics in the ICUs for the urgency of initiating an empirical therapy, a practice adopted globally due to the inherent delay of conventional culture and susceptibility testing. Accordingly, up-to-date hospital antibiograms based on local epidemiological data are fundamental for guiding clinicians to select the most appropriate empirical treatment not only to ensure optimal patient outcomes but also to de-escalate the mounting risk of multidrug resistance.
The convergence of multiple antibiotic resistance and virulence genes in the same strain enhances its pathogenicity and complicates its treatment in an era where we are running out of antibiotics [55]. Although CZA has emerged over the last few years as a newly proposed antimicrobial agent to treat CRKP infections, it is still ineffective against NDM-producing CRKP [56]. Comparing the frequency of different detected carbapenemases, blaNDM was found to prevail in 16/17 isolates, rendering CZA of a circumscribed clinical utility. The validity of our data was corroborated by a 1-year-cross-sectional study on Gram-negative bacteria conducted at Mansoura University Hospitals in 2019 [57] and a 2-year study on Enterobacteriaceae across 40 countries worldwide [58], wherein blaNDM was the predominant gene correlated with carbapenem resistance.
Comparative analysis of phenotypic-genotypic antimicrobial resistance patterns (Fig. 2 and Additional file 2: Table S5) showed high concordance, especially for β-lactams, β-lactams combinations, fluoroquinolones, tetracyclines, folate pathway antagonist, and polymyxins. Some discrepancies were observed in macrolides and aminoglycosides phenotypic-genotypic profile, where a phenotypically resistant pattern with no corresponding resistance determinants could be justified by the existence of other resistance genes or mechanisms that have not been explored in the study, and a phenotypically susceptible pattern displayed in the presence of resistant determinants could be attributed to the harboring of silent resistance genes.
In terms of colistin resistome analysis, chromosomally encoded genes: phoPQ, pmrAB, crrB, and mgrB locus with its transcriptional regulator gene kdgR, and its genetic environment including yobH, yebO, yobF, and cspC, were analyzed in silico along with the investigation of the acquired plasmid-borne mcr genes. These genes were chosen based on being the most reported mechanisms worldwide in ColRKp [59]. Additional chromosomal genes including pmrC, pmrD, arnBCADTEF operon, and the global transcriptional regulator ramA that activates genes responsible for LPS synthesis and Lipid A modification were inspected as they have been suggested to confer a secondary colistin resistome [60].
The predominant mechanism mediating colistin resistance was found to be via the genetic modulation of mgrB locus that occurred in 82.35% of the collected isolates. Our results are in line with the numerous number of reports nominating mgrB mutation to be the most frequently occurring mechanism involved in colistin resistance [59]. MgrB protein functions as a negative feedback regulatory component of the PhoPQ 2-component system (2CS) [12]. It represses the formation of the active phosphorylated PhoP, which in turn decreases PhoPQ signal transduction to arnBCADTEF and pmrCAB operons, thus lowering L-Ara4N and pEtN production that relies on the activation of the former operons [12]. Accordingly, genetic alterations in mgrB result in the upregulation of PhoPQ and PmrAB 2CS that are connected through PmrD protein, thereby promoting the production of the LPS-modifying molecules and consequently conferring colistin resistance [61]. Insertional inactivation of mgrB locus was on the top tier of the detected mgrB alterations, with ISKpn14, a member of IS1 family, being the most predominant in 6/8 isolates, while a member of IS5 family, ISKpn26, inactivated mgrB in the other two isolates. Our data is consolidated by the existing literature that highlights mgrB insertional inactivation as the most common pathway of MgrB dysfunction [9]. However, the prevalent occurrence of ISKpn14 is incompatible with the preexisting studies stating that IS5 family elements cause the most frequent inactivation of mgrB [9]. This might be attributed to the different geographical regions in which the studies were conducted, hence, studies from Saudi Arabia and China were consistent with our findings [62, 63]. ISKpn14 transposed at nucleotide positions − 37, + 35, + 81, + 118, and + 119 with the first transposition being in the promoter region which is presumed to negatively impact the expression of the gene [12] and the remaining transpositions being within mgrB resulting in gene splitting and generation of malfunctioning MgrB [64]. While the transposition of ISKpn26 was at nucleotide position + 74 of mgrB and this position seems to be a hotspot for the insertion sequence as reported in earlier studies [64, 65]. Among other mutational events occurring in mgrB are the G37S deleterious mutation in MgrB and the deletion of ∼ 1.7 kb segment comprising the entire mgrB locus, yebO, yobF, and cspC, as well as a partial sequence of yobH. In a study conducted in Brazil in 2021, a similar colistin resistance mechanism was reported and was attributed to the deletion of ∼ 1.3 kb segment including kdgR, yobH, mgrb, and yebO [66]. Importantly, the two latter mutational and deletion events had been experimentally validated by a complementation assay using pACYC-mgrB plasmid containing wild-type yobH-mgrB-yebO in a study conducted by Cannatelli et al. where colistin sensitivity was restored [67]. Additionally, a mutation of guanine to adenine at position − 10 upstream mgrB is speculated to confer colistin resistance as the mutation occurred at a critical region where the ribosomal binding site is typically situated [68], thereby this might affect the binding efficiency of the ribosome to the mRNA and consequently impacts MgrB synthesis process.
Other molecular mechanisms of colistin resistance are the mutations occurring in genes of the regulatory PhoPQ and PmrAB 2CS activating the signaling pathways of the 2CS [12]. This activation will eventually lead to the overproduction of L-Ara4N and pEtN and the modification of LPS, rendering K. pneumoniae resistant to colistin [12]. In the current study, we detected novel and preexisting mutations linked to colistin resistance. To the best of our knowledge, L322Q and Q435H substitutions in PhoQ and T89P substitution in PmrB, are unprecedented deleterious mutations conferring colistin resistance as predicted by PROVEAN tool. Nonetheless, deleterious alterations in PmrB (T134P) and PmrA (G53V and D86E) had been reported by prior studies [69–71]. Other mutations in PmrC and across arnBCADTEF operon (Fig. 3) reflected the divergent mutation profiles displayed by ColRKp isolates as stated by earlier reports [63, 72], however, the contribution of these mutations to colistin resistance remains to be unclear and requires further investigation and validation.
CrrAB, an additional 2CS, was completely absent in isolates of ST14 and ST383 lineages. The absence of this system is not reported to be associated with colistin resistance [63] due to its variable presence in K. pneumoniae strains [73].
Collectively, our results imply that chromosomal mutations were the main driver for colistin resistance in tested isolates, whereas, the plasmid-encoded mcr-1.1 gene, which is more readily transmissible, was harbored by a single isolate of ST525 clone. ST525 first emerged as a new high-risk clone in Hungary in 2006, causing multiple nosocomial outbreaks in distant places around the country until 2012 [74]. Since then, other reports on ST525 in Norway [46], Romania [75], Tunisia [76], and Iran [47] emerged, threatening the public health situation globally. This high-risk clone detected in our study exhibited an XDR profile along with a dual chromosomal and plasmid-mediated colistin resistance mechanism.
The mcr-1.1 gene was carried on pEGY_KP9814_MCR1, a multi-replicon IncHI2/IncHI2A plasmid. The backbone of this multi-replicon plasmid was previously identified in Klebsiella-, E. coli-, and Salmonella-derived mcr plasmids worldwide [77, 78]. Strikingly, the notable resemblance of pEGY_KP9814_MCR1 in K. pneumoniae obtained from a clinical origin in the current study to those sourced from E. coli of food and animal origins in Egypt (pEGY1-MCR-1 [79] and pEGYMCR_IncHI2 [80]), reflects the circulating tendency of this plasmid for trafficking between different members of Enterobacteriaceae and among different sources for which the unconstrained colistin use as an antibiotic-fortified feed and growth promoter in animals could be attributed. Our findings are in agreement with previous studies reported from other parts of the world pointing to the zoonotic transmission of mcr-bearing plasmids to humans [81–83]. This provides direct evidence in support of One Health concept that emphasizes the transmission of drug resistance across the environment, humans, and animals [84]. Regarding this, enforcement legislation on the irrational use of colistin in the agriculture sector is of significant importance along with providing professional education and training on AMR in veterinary, food production, and agriculture sectors for the aim of curbing the dissemination of colistin resistance in the animal food chain. Moreover, the similarity noted between pEGY_KP9814_MCR1 and the plasmids recovered from clinical K. pneumoniae in Asia (pAN65-1 [85], pKP121-1-mcr [86], pKP14052-MCR-1 [87]) indicates the epidemic trait of this plasmid, disseminating colistin resistance between continents.
Prior sequence analysis of mcr-1.1 environment showed that the gene is flanked by a composite transposon, two copies of ISApl1, that promotes its transposition and mobilization between DNA molecules [88]. Across evolutionary changes, this composite transposon has lost one or both copies of ISApl1 which will probably limit its transposition and prompt transfixing of mcr-1.1 cassette into the carrier plasmid facilitating its dissemination [89]. Therefore, the aforementioned data explains the variable presence of ISApl1 bracketing mcr-1.1 either in the designated pEGY_KP9814_MCR1 plasmid or the previously published plasmids used for comparison. Overall, this is the first report for mcr-1.1-borne plasmid sourced from clinical K. pneumoniae belonging to ST525 high-risk clone.
The present study adds to the insufficiently available literature on genomic characterization of ColRKp in Egypt and emphasizes how genomics and WGS-based analysis are indispensable to gain better insights into the genetic basis of bacterial resistance to antimicrobial agents. Meanwhile, we acknowledge the limitations of the study. These include the small number of tested isolates which could serve as a preliminary step toward conducting a broader surveillance program within our local vicinity. The virulence profile was predicted based on the isolates genome without conducting phenotypic detection of virulence attributes. Additionally, the study focused on genetic characterization using WGS rather than transcriptomic analysis, therefore the expression levels of genes contributing to colistin resistance such as pmrC, arnBCADTEF, ramA, and genes encoding efflux systems (kpnEF and acrAB) were not measured.
Conclusion
The current study unprecedently reports a snapshot of the genomic profile of ColRKp clinical isolates in the Egyptian ICUs based on WGS data. The emergence of pathogenic colistin-carbapenem-resistant K. pneumoniae foreshadows a menacing crisis as the clinical utility of the last-resort antibiotics is significantly diminishing. Here, we present the divergent molecular mechanisms involved in colistin resistance and, hence, provide crucial information to optimize patient care and contain the spread of these pathogens.
Supplementary Information
Abbreviations
- CRKP
Carbapenem-resistant K. pneumoniae
- LPS
Lipopolysaccharide
- ColRKp
Colistin-resistant K. pneumoniae
- mcr
Mobile colistin resistance gene
- MPNP
Modified rapid polymyxin Nordmann/Poirel
- Col-R
Colistin-resistant
- Col-S
Colistin-sensitive
- CLSI
Clinical Laboratory Standards Institute
- BMD
Broth microdilution
- MLST
Multilocus sequencing typing
- AMR
Antimicrobial resistance
- mini-BAL
Mini-bronchoalveolar lavage
- ST
Sequence type
- CPS
Capsule polysaccharide
- XDR
Extensively drug-resistant
- WT
Wild-type
- ESBL
Extended-spectrum β-lactamase
- PR
Promoter region
- 2CS
2-Component system
Author contributions
ETA: methodology, validation, bioinformatic analysis, data curation, writing—original draft and preparing figures. AMK: conceptualization, validation, writing—review and editing. ASZ: conceptualization, validation, bioinformatic analysis, data curation, writing—review and editing. DJB, WGS, bioinformatic analysis, validation, writing—review. NMM: conceptualization, validation, data curation, writing—review and editing, and project administration. All authors read and approved the final manuscript.
Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors declare that they did not receive any funding or grants to support their research.
Availability of data and materials
The WGS dataset generated during the current study was deposited at NCBI repository under BioProject number PRJNA917066 with samples accession numbers (SAMN32518852–SAMN32518868) which correspond to isolates from K1-K17 https://www.ncbi.nlm.nih.gov/search/all/?term=PRJNA917066. Mutated mgrB of the sequenced isolates can be found at NCBI with GenBank accession numbers (OR146624-OR146636). Plasmid designated pEGY_KP9814_MCR1 is deposited at NCBI with accession number: OQ215737 https://www.ncbi.nlm.nih.gov/nuccore/OQ215737.1.
Declarations
Ethics approval and consent to participate
The study was approved by the ethics committee of the Faculty of Medicine, Alexandria University under IRB number: 00012098 and FWA number: 00018699.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589–603. doi: 10.1128/CMR.11.4.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10(1):22. doi: 10.1186/s13756-020-00871-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Al-Baz AA, Maarouf A, Marei A, Abdallah AL. Prevalence and antibiotic resistance profiles of carbapenem-resistant Klebsiella pneumoniae isolated from Tertiary Care Hospital, Egypt. Egypt J Hosp Med. 2022;88(1):2883–2890. doi: 10.21608/ejhm.2022.242765. [DOI] [Google Scholar]
- 4.Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the british Society for Antimicrobial Chemotherapy/Healthcare infection Society/British infection Association Joint Working Party. J Antimicrob Chemother. 2018;73(Suppl 3):iii2–iii78. doi: 10.1093/jac/dky027. [DOI] [PubMed] [Google Scholar]
- 5.Kotb S, Lyman M, Ismail G, Abd El Fattah M, Girgis SA, Etman A, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare-associated infections surveillance data, 2011–2017. Antimicrob Resist Infect Control. 2020;9(1):2. doi: 10.1186/s13756-019-0639-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–1798. doi: 10.3201/eid1710.110655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017. Report No. 9789240026438 (electronic version) 9789240026421 (print version) Contract No. WHO/EMP/IAU/2017.12.
- 8.El-Sayed Ahmed MAE, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019) Emerg Microbes Infect. 2020;9(1):868–885. doi: 10.1080/22221751.2020.1754133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents. 2016;48(6):583–591. doi: 10.1016/j.ijantimicag.2016.06.023. [DOI] [PubMed] [Google Scholar]
- 10.Sameni F, Ghazi M, Dadashi M, Bostanshirin N, Al-Dahmoshi HOM, Khosravi-Dehaghi N, et al. Global distribution, genotypes and prevalent sequence types of colistin-resistant Klebsiella pneumoniae isolated from clinical samples; a systematic review. Gene Rep. 2022;28:101635. doi: 10.1016/j.genrep.2022.101635. [DOI] [Google Scholar]
- 11.Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients. Ann Clin Microbiol Antimicrob. 2019;18(1):40. doi: 10.1186/s12941-019-0339-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Berglund B. Acquired resistance to colistin via chromosomal and plasmid-mediated mechanisms in Klebsiella pneumoniae. Infect Microbes Dis. 2019;1(1):10–19. doi: 10.1097/IM9.0000000000000002. [DOI] [Google Scholar]
- 13.Wang C, Feng Y, Liu L, Wei L, Kang M, Zong Z. Identification of novel mobile colistin resistance gene mcr-10. Emerg Microbes Infect. 2020;9(1):508–516. doi: 10.1080/22221751.2020.1732231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557–596. doi: 10.1128/CMR.00064-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Jeannot K, Bolard A, Plesiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49(5):526–535. doi: 10.1016/j.ijantimicag.2016.11.029. [DOI] [PubMed] [Google Scholar]
- 16.WHO. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization; 2021. Contract No. WHO/MHP/HPS/EML/2021.02.
- 17.Aris P, Robatjazi S, Nikkhahi F, Amin Marashi SM. Molecular mechanisms and prevalence of colistin resistance of Klebsiella pneumoniae in the Middle East region: a review over the last 5 years. J Glob Antimicrob Resist. 2020;22:625–630. doi: 10.1016/j.jgar.2020.06.009. [DOI] [PubMed] [Google Scholar]
- 18.Ahmed ZS, Elshafiee EA, Khalefa HS, Kadry M, Hamza DA. Evidence of colistin resistance genes (mcr-1 and mcr-2) in wild birds and its public health implication in Egypt. Antimicrob Resist Infect Control. 2019;8:197. doi: 10.1186/s13756-019-0657-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Abozahra R, Gaballah A, Abdelhamid SM. Prevalence of the colistin resistance gene MCR-1 in colistin-resistant Klebsiella pneumoniae in Egypt. AIMS Microbiol. 2023;9(2):177–194. doi: 10.3934/microbiol.2023011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Elmonir W, Abd El-Aziz NK, Tartor YH, Moustafa SM, Abo Remela EM, Eissa R, et al. Emergence of colistin and carbapenem resistance in extended-spectrum β-lactamase producing Klebsiella pneumoniae isolated from chickens and humans in Egypt. Biology. 2021;10(5):373. doi: 10.3390/biology10050373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Elbaradei A, Sayedahmed MS, El-Sawaf G, Shawky SM. Screening of mcr-1 among Gram-negative bacteria from different clinical samples from ICU patients in Alexandria, Egypt: one-year study. Pol J Microbiol. 2022;71(1):83–90. doi: 10.33073/pjm-2022-011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Nordmann P, Jayol A, Poirel L. Rapid detection of polymyxin resistance in Enterobacteriaceae. Emerg Infect Dis. 2016;22(6):1038–1043. doi: 10.3201/eid2206.151840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Esposito F, Fernandes MR, Lopes R, Muñoz M, Sabino CP, Cunha MP, et al. Detection of colistin-resistant MCR-1-positive Escherichia coli by use of assays based on inhibition by EDTA and zeta potential. J Clin Microbiol. 2017;55(12):3454–3465. doi: 10.1128/JCM.00835-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Zakaria AS, Edward EA, Mohamed NM. Genomic insights into a colistin-resistant uropathogenic Escherichia coli strain of O23:H4-ST641 lineage harboring mcr-1.1 on a conjugative IncHI2 plasmid from Egypt. Microorganisms. 2021;9(4):799. doi: 10.3390/microorganisms9040799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.CLSI. Performance standards for antimicrobial susceptibility testing, 31st ed. CLSI Supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2021 [DOI] [PMC free article] [PubMed]
- 26.FDA Database. https://www.fda.gov/drugs/development-resources/tigecycline-injection-products. Accessed 5 July 2020.
- 27.bcl2fastq conversion software v2.20. Illumina, San Diego, CA. 2019. https://support.illumina.com/content/dam/illumina-support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v2-20-software-guide-15051736-03.pdf.
- 28.Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890. doi: 10.1093/bioinformatics/bty560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29(8):1072–1075. doi: 10.1093/bioinformatics/btt086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Manni M, Berkeley MR, Seppey M, Simão FA, Zdobnov EM. BUSCO update: novel and streamlined workflows along with broader and deeper phylogenetic coverage for scoring of eukaryotic, prokaryotic, and viral genomes. Mol Biol Evol. 2021;38(10):4647–4654. doi: 10.1093/molbev/msab199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 2005;33(Suppl 1):D325–D328. doi: 10.1093/nar/gki008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006;34(Database issue):D32–D36. doi: 10.1093/nar/gkj014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O. Solving the problem of comparing whole bacterial genomes across different sequencing platforms. PLoS ONE. 2014;9(8):e104984. doi: 10.1371/journal.pone.0104984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Letunic I, Bork P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49(W1):W293–W296. doi: 10.1093/nar/gkab301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455–477. doi: 10.1089/cmb.2012.0021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016;44(14):6614–6624. doi: 10.1093/nar/gkw569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014;58(7):3895–3903. doi: 10.1128/AAC.02412-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75(12):3491–3500. doi: 10.1093/jac/dkaa345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Gilchrist CLM, Chooi Y-H. Clinker & clustermap.js: automatic generation of gene cluster comparison figures. Bioinformatics. 2021;37(16):2473–2475. doi: 10.1093/bioinformatics/btab007. [DOI] [PubMed] [Google Scholar]
- 40.Carniel E. The Yersinia high-pathogenicity island: an iron-uptake island. Microbes Infect. 2001;3(7):561–569. doi: 10.1016/S1286-4579(01)01412-5. [DOI] [PubMed] [Google Scholar]
- 41.Uzairue LI, Rabaan AA, Adewumi FA, Okolie OJ, Folorunso JB, Bakhrebah MA, et al. Global prevalence of colistin resistance in Klebsiella pneumoniae from bloodstream infection: a systematic review and meta-analysis. Pathogens. 2022;11(10):1092. doi: 10.3390/pathogens11101092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Pitt ME, Elliott AG, Cao MD, Ganesamoorthy D, Karaiskos I, Giamarellou H, et al. Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant Klebsiella pneumoniae. Microb Genom. 2018;4(3):e000158. doi: 10.1099/mgen.0.000158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Nawfal Dagher T, Azar E, Al-Bayssari C, Chamieh AS, Rolain JM. First detection of colistin-resistant Klebsiella pneumoniae in association with NDM-5 carbapenemase isolated from clinical lebanese patients. Microb Drug Resist. 2019;25(6):925–930. doi: 10.1089/mdr.2018.0383. [DOI] [PubMed] [Google Scholar]
- 44.Sabirova JS, Xavier BB, Coppens J, Zarkotou O, Lammens C, Janssens L, et al. Whole-genome typing and characterization of blaVIM19-harbouring ST383 Klebsiella pneumoniae by PFGE, whole-genome mapping and WGS. J Antimicrob Chemother. 2016;71(6):1501–1509. doi: 10.1093/jac/dkw003. [DOI] [PubMed] [Google Scholar]
- 45.ElMahallawy HA, Zafer MM, Amin MA, Ragab MM, Al-Agamy MH. Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt. Infect Dis. 2018;50(7):560–564. doi: 10.1080/23744235.2018.1428824. [DOI] [PubMed] [Google Scholar]
- 46.Samuelsen O, Naseer U, Karah N, Lindemann PC, Kanestrom A, Leegaard TM, et al. Identification of Enterobacteriaceae isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. J Antimicrob Chemother. 2013;68(7):1682–1685. doi: 10.1093/jac/dkt058. [DOI] [PubMed] [Google Scholar]
- 47.Pishnian Z, Haeili M, Feizi A. Prevalence and molecular determinants of colistin resistance among commensal Enterobacteriaceae isolated from poultry in northwest of Iran. Gut Pathog. 2019;11(1):2. doi: 10.1186/s13099-019-0282-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, et al. The diversity of Klebsiella pneumoniae surface polysaccharides. Microb Genom. 2016;2(8):e000073. doi: 10.1099/mgen.0.000073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–359. doi: 10.1038/s41579-019-0315-1. [DOI] [PubMed] [Google Scholar]
- 50.Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015;83(8):3325–3333. doi: 10.1128/IAI.00430-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Turton JF, Payne Z, Coward A, Hopkins KL, Turton JA, Doumith M, et al. Virulence genes in isolates of Klebsiella pneumoniae from the UK during 2016, including among carbapenemase gene-positive hypervirulent K1-ST23 and ‘non-hypervirulent’ types ST147, ST15 and ST383. J Med Microbiol. 2018;67(1):118–128. doi: 10.1099/jmm.0.000653. [DOI] [PubMed] [Google Scholar]
- 52.Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis. 2018;18(1):37–46. doi: 10.1016/S1473-3099(17)30489-9. [DOI] [PubMed] [Google Scholar]
- 53.Furlan JPR, Savazzi EA, Stehling EG. Genomic insights into multidrug-resistant and hypervirulent Klebsiella pneumoniae co-harboring metal resistance genes in aquatic environments. Ecotoxicol Environ Saf. 2020;201:110782. doi: 10.1016/j.ecoenv.2020.110782. [DOI] [PubMed] [Google Scholar]
- 54.Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478–1487. doi: 10.1001/jama.2020.2717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Edward EA, Mohamed NM, Zakaria AS. Whole genome characterization of the high-risk clone ST383 Klebsiella pneumoniae with a simultaneous carriage of blaCTX-M-14 on IncL/M plasmid and blaCTX-M-15 on convergent IncHI1B/IncFIB plasmid from Egypt. Microorganisms. 2022;10(6):1097. doi: 10.3390/microorganisms10061097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis. 2021;40(10):2053–2068. doi: 10.1007/s10096-021-04296-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Elrahem AA, El-Mashad N, Elshaer M, Ramadan H, Damiani G, Bahgat M, et al. Carbapenem resistance in Gram-negative bacteria: a hospital-based study in Egypt. Medicina. 2023;59(2):285. doi: 10.3390/medicina59020285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, et al. Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(2):1067–1078. doi: 10.1128/AAC.02379-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Yusof NY, Norazzman NII, Hakim S, Azlan MM, Anthony AA, Mustafa FH, et al. Prevalence of mutated colistin-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. Trop Med Infect Dis. 2022;7(12):414. doi: 10.3390/tropicalmed7120414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Binsker U, Kasbohrer A, Hammerl JA. Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis. FEMS Microbiol Rev. 2022;46(1):fuab049. doi: 10.1093/femsre/fuab049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Gogry FA, Siddiqui MT, Sultan I, Haq QMR. Current update on intrinsic and acquired colistin resistance mechanisms in bacteria. Front Med. 2021;8:677720. doi: 10.3389/fmed.2021.677720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Uz Zaman T, Albladi M, Siddique MI, Aljohani SM, Balkhy HH. Insertion element mediated mgrB disruption and presence of ISKpn28 in colistin-resistant Klebsiella pneumoniae isolates from Saudi Arabia. Infect Drug Resist. 2018;11:1183–1187. doi: 10.2147/IDR.S161146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Li Z, Liu X, Lei Z, Li C, Zhang F, Wu Y, et al. Genetic diversity of polymyxin-resistance mechanisms in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: a multicenter study in China. Microbiol Spectr. 2023;11(2):e05231-22. doi: 10.1128/spectrum.05231-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Yang T-Y, Wang S-F, Lin J-E, Griffith BTS, Lian S-H, Hong Z-D, et al. Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents. 2020;55(3):105894. doi: 10.1016/j.ijantimicag.2020.105894. [DOI] [PubMed] [Google Scholar]
- 65.da Silva DM, Faria-Junior C, Nery DR, de Oliveira PM, Silva LD, Alves EG, et al. Insertion sequences disrupting mgrB in carbapenem-resistant Klebsiella pneumoniae strains in Brazil. J Glob Antimicrob Resist. 2021;24:53–57. doi: 10.1016/j.jgar.2020.11.003. [DOI] [PubMed] [Google Scholar]
- 66.de Araujo Longo LG, Fontana H, Santos de Sousa V, Chilinque Zambao da Silva N, Souto Martins I, Meurer Moreira B. Emergence of mgrB locus deletion mediating polymyxin resistance in pandemic KPC-producing Klebsiella pneumoniae ST15 lineage. J Med Microbiol. 2021;70(3):001309. doi: 10.1099/jmm.0.001309. [DOI] [PubMed] [Google Scholar]
- 67.Cannatelli A, Giani T, D’Andrea MM, Di Pilato V, Arena F, Conte V, et al. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother. 2014;58(10):5696–5703. doi: 10.1128/AAC.03110-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Suzek BE, Ermolaeva MD, Schreiber M, Salzberg SL. A probabilistic method for identifying start codons in bacterial genomes. Bioinformatics. 2001;17(12):1123–1130. doi: 10.1093/bioinformatics/17.12.1123. [DOI] [PubMed] [Google Scholar]
- 69.Mills JP, Rojas LJ, Marshall SH, Rudin SD, Hujer AM, Nayak L, et al. Risk factors for and mechanisms of colistin resistanc among Enterobacterales: getting at the CORE of the issue. Open Forum Infect Dis. 2021;8(7):ofab145. doi: 10.1093/ofid/ofab145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Arena F, Di Pilato V, Vannetti F, Fabbri L, Antonelli A, Coppi M, et al. Population structure of KPC carbapenemase-producing Klebsiella pneumoniae in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity. Microb Genom. 2020;6(1):e000308. doi: 10.1099/mgen.0.000308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Zhao J, Li Z, Zhang Y, Liu X, Lu B, Cao B. Convergence of MCR-8.2 and chromosome-mediated resistance to colistin and tigecycline in an NDM-5-producing ST656 Klebsiella pneumoniae isolate from a lung transplant patient in China. Front Cell Infect Microbiol. 2022;12:922031. doi: 10.3389/fcimb.2022.922031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Pragasam AK, Shankar C, Veeraraghavan B, Biswas I, Nabarro LE, Inbanathan FY, et al. Molecular mechanisms of colistin resistance in Klebsiella pneumoniae causing bacteremia from India—a first report. Front Microbiol. 2016;7:2135. doi: 10.3389/fmicb.2016.02135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, et al. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother. 2015;59(1):536–543. doi: 10.1128/AAC.04037-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Damjanova I, Jakab M, Urbán E, Farkas M, Juhász Á, Katona K, et al. Klebsiella pneumoniae ST525: the new high-risk multidrug-resistant epidemic clone in Hungary. Dissemination of ESBLs in Europe and beyond. Berlin: ESCMID eLibrary; 2013. [Google Scholar]
- 75.Teban-Man A, Farkas A, Baricz A, Hegedus A, Szekeres E, Pârvu M, et al. Wastewaters, with or without hospital contribution, harbour MDR, carbapenemase-producing, but not hypervirulent Klebsiella pneumoniae. Antibiotics. 2021;10(4):361. doi: 10.3390/antibiotics10040361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Messaoudi A, Haenni M, Bouallègue O, Saras E, Chatre P, Chaouch C, et al. Dynamics and molecular features of OXA-48-like-producing Klebsiella pneumoniae lineages in a tunisian hospital. J Glob Antimicrob Resist. 2020;20:87–93. doi: 10.1016/j.jgar.2019.07.005. [DOI] [PubMed] [Google Scholar]
- 77.Jamin C, Sanders BK, Zhou M, Costessi A, Duijsings D, Kluytmans JAJW, et al. Genetic analysis of plasmid-encoded mcr-1 resistance in Enterobacteriaceae derived from poultry meat in the Netherlands. JAC Antimicrob Resist. 2021;3(4):dlab156. doi: 10.1093/jacamr/dlab156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Yang T, Li W, Cui Q, Qin X, Li B, Li X, et al. Distribution and transmission of colistin resistance genes mcr-1 and mcr-3 among nontyphoidal Salmonella isolates in China from 2011 to 2020. Microbiol Spectr. 2023;11(1):e0383322. doi: 10.1128/spectrum.03833-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Hammad AM, Hoffmann M, Gonzalez-Escalona N, Abbas NH, Yao K, Koenig S, et al. Genomic features of colistin resistant Escherichia coli ST69 strain harboring mcr-1 on IncHI2 plasmid from raw milk cheese in Egypt. Infect Genet Evol. 2019;73:126–131. doi: 10.1016/j.meegid.2019.04.021. [DOI] [PubMed] [Google Scholar]
- 80.Sadek M, Ortiz de la Rosa JM, Abdelfattah Maky M, Korashe Dandrawy M, Nordmann P, Poirel L. Genomic features of MCR-1 and extended-spectrum beta-lactamase-producing Enterobacterales from retail raw chicken in Egypt. Microorganisms. 2021;9(1):195. doi: 10.3390/microorganisms9010195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Zhang XF, Doi Y, Huang X, Li HY, Zhong LL, Zeng KJ, et al. Possible transmission of mcr-1-harboring Escherichia coli between companion animals and human. Emerg Infect Dis. 2016;22(9):1679–1681. doi: 10.3201/eid2209.160464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Trung NV, Matamoros S, Carrique-Mas JJ, Nghia NH, Nhung NT, Chieu TT, et al. Zoonotic transmission of mcr-1 colistin resistance gene from small-scale poultry farms, Vietnam. Emerg Infect Dis. 2017;23(3):529–532. doi: 10.3201/eid2303.161553. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Zhou Y, Farzana R, Sihalath S, Rattanavong S, Vongsouvath M, Mayxay M, et al. A one-health sampling strategy to explore the dissemination and relationship between colistin resistance in human, animal, and environmental sectors in Laos. Engineering. 2022;15:45–56. doi: 10.1016/j.eng.2022.01.013. [DOI] [Google Scholar]
- 84.Collignon PJ, McEwen SA. One health—its importance in helping to better control antimicrobial resistance. Trop Med Infect Dis. 2019;4(1):22. doi: 10.3390/tropicalmed4010022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Song Z, Qin Y, Peng Y, Huang M, Hua Y, Jiang H, et al. Carbapenem-resistant Klebsiella pneumoniae (CRKP) transfers conjugative plasmids containing blaNDM-5 and mcr-1 genes via outer membrane vesicles (OMVs). Res Sq; 2022.
- 86.Ruan Z, Sun Q, Jia H, Huang C, Zhou W, Xie X, et al. Emergence of a ST2570 Klebsiella pneumoniae isolate carrying mcr-1 and blaCTX-M-14 recovered from a bloodstream infection in China. Clin Microbiol Infect. 2019;25(7):916–918. doi: 10.1016/j.cmi.2019.02.005. [DOI] [PubMed] [Google Scholar]
- 87.Lin Y-C, Kuroda M, Suzuki S, Mu J-J. Emergence of the mcr-1 colistin resistance gene in extended-spectrum β-lactamase-producing Klebsiella pneumoniae in Taiwan. J Glob Antimicrob Resist. 2021;24:278–284. doi: 10.1016/j.jgar.2020.12.024. [DOI] [PubMed] [Google Scholar]
- 88.Ji X, Zheng B, Berglund B, Zou H, Sun Q, Chi X, et al. Dissemination of extended-spectrum β-lactamase-producing Escherichia coli carrying mcr-1 among multiple environmental sources in rural China and associated risk to human health. Environ Pollut. 2019;251:619–627. doi: 10.1016/j.envpol.2019.05.002. [DOI] [PubMed] [Google Scholar]
- 89.Snesrud E, He S, Chandler M, Dekker JP, Hickman AB, McGann P, et al. A model for transposition of the colistin resistance gene mcr-1 by ISApl1. Antimicrob Agents Chemother. 2016;60(11):6973–6976. doi: 10.1128/AAC.01457-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The WGS dataset generated during the current study was deposited at NCBI repository under BioProject number PRJNA917066 with samples accession numbers (SAMN32518852–SAMN32518868) which correspond to isolates from K1-K17 https://www.ncbi.nlm.nih.gov/search/all/?term=PRJNA917066. Mutated mgrB of the sequenced isolates can be found at NCBI with GenBank accession numbers (OR146624-OR146636). Plasmid designated pEGY_KP9814_MCR1 is deposited at NCBI with accession number: OQ215737 https://www.ncbi.nlm.nih.gov/nuccore/OQ215737.1.